A protest has been held outside the Senedd over the lack of availability of a treatment which has been hailed as a "major step forward" for people with the condition.
Last year the National Institute for Health and Care Excellence (NICE), which helps decide which new treatments should be available on the NHS in England and Wales, rejected the drug Orkambi, which has been shown in clinical trials to improve lung function and respiratory symptoms in people with the genetic condition.
The charity the Cystic Fibrosis Trust said that since Nice undertook its appraisal, new data had been published that suggested Orkambi almost halved the rate of decline in lung function in people with the disease.
It said that studies have shown that if children with cystic fibrosis start taking Orkambi early enough they could have a near-normal life expectancy.
Cystic fibrosis is a life-shortening genetic condition that causes fatal lung damage. Only around half of people with cystic fibrosis live to celebrate their 40th birthday.
Cystic fibrosis is a life-shortening genetic condition that causes lung damage. Only around half of patients reach their 40th birthday.Read the full story ›
A monthly report which looks at the way the NHS in Wales is working has said that 'NHS Wales performance is stable, despite growing demand'.Read the full story ›
Cliff Powis from Abertillery has worked for the NHS for 43 years.Read the full story ›
A new drug which could extend the lives of women with advanced breast cancer has been approved for routine use on the NHS in Wales.Read the full story ›
Welsh Ambulance Service ‘heading in the right direction’ says Healthcare Inspectorate Wales.Read the full story ›
'Patients Know Best' has been described as a secure medical version of Facebook which allows patients to track their own treatment.Read the full story ›
Abul Hashem's life seemed normal, having migrated from Bangladesh 30 years ago. But since his wife's death he says he feels lonely.Read the full story ›